Fridriksdottir Hafrun
- SEC CIK
- 0001561458
No open-market purchases or sales filed in the past year.
Current role at each company
- TEVA Teva Pharmaceutical Industries LtdExecutive VP, Global R&Das of May 19, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Fridriksdottir Hafrun as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2022 (view filing) | May 17 | 2 days | Fridriksdottir HafrunExecutive VP, Global R&D | SSale | −130.0K | $8.22 | −$1.07M | −98.9%1.39K after | |
| Mar 8, 2022 (view filing) | Mar 4-7 | 4 days | Fridriksdottir HafrunExecutive VP, Global R&D | SSale | −33.6K | $7.45 | −$250.2K | −21.0%126.1K after | 3 lots |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Fridriksdottir HafrunExecutive VP, Global R&D | SSale | −7.59K | $8.14 | −$61.8K | −10.4%65.5K after | |
| Feb 10, 2022 (view filing) | Feb 9 | 1 day | Fridriksdottir HafrunExecutive VP, Global R&D | SSale | −6.12K | $9.06 | −$55.4K | −10.6%51.4K after | |
| Aug 12, 2021 (view filing) | Aug 10 | 2 days | Fridriksdottir HafrunExecutive VP, Global R&D | SSale | −50.9K | $9.95 | −$506.1K | −55.1%41.4K after |